Study of VIR-2482 in Healthy Volunteers

• Status: Active, not recruiting
• Trial end date: 2021-11-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a phase 1 study in which healthy volunteers will receive VIR-2482 or placebo and will be assessed for safety, pharmacokinetics, and immunogenicity of VIR-2482 in preventing Influenza A illness.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Vir Biotechnology, Inc.

Criteria

Inclusion Criteria:

• Healthy Male or Female age 18 to < 65 years

• Body mass index (BMI) of 18.0 kg/m^2 to 32.0kg/m^2

Exclusion Criteria:

• Any clinically significant chronic or acute medical condition that makes the volunteer unsuitable for participation

• History of influenza-like illness or confirmed influenza infection within 3 months prior to randomization.

• Fever-like illness within 5 days of randomization.

• History or clinical evidence of conditions considered high risk for developing influenza-related complications.